Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

被引：2
|
作者：
Ishido, Shun [1 ]
Tamaki, Nobuharu [1 ]
Inada, Kento [1 ]
Itakura, Jun [1 ]
Takahashi, Yuka [1 ]
Uchihara, Naoki [1 ]
Suzuki, Keito [1 ]
Tanaka, Yuki [1 ]
Miyamoto, Haruka [1 ]
Yamada, Michiko [1 ]
Matsumoto, Hiroaki [1 ]
Nobusawa, Tsubasa [1 ]
Keitoku, Taisei [1 ]
Takaura, Kenta [1 ]
Tanaka, Shohei [1 ]
Maeyashiki, Chiaki [1 ]
Yasui, Yutaka [1 ]
Tsuchiya, Kaoru [1 ]
Nakanishi, Hiroyuki [1 ]
Kurosaki, Masayuki [1 ,2 ]
Izumi, Namiki [1 ]
机构：
[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan
[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan
来源：
CLINICAL CASE REPORTS | 2023年 / 11卷 / 07期
关键词：
comprehensive genomic profiling; fibroblast growth factor receptor 2; intrahepatic cholangiocarcinoma; pemigatinib; PHASE-II; MULTICENTER; GEMCITABINE; CISPLATIN; S-1;
D O I：
10.1002/ccr3.7664
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Key Clinical MessageThe liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Cholangiocarcinoma patients with FGFR2 fusions/ rearrangements but primary refractory to pemigatinib: the real challenge?
    Rizzo, A.
    Ricci, A. D.
    Brandi, G.
    ESMO OPEN, 2024, 9 (10)
  • [22] A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate mechanism of therapeutic response and resistance to FGFR inhibitors
    Kendre, Gajanan
    Marhenke, Silke
    Lorz, Georgina
    Saborowski, Michael
    Vogel, Arndt
    Saborowski, Anna
    JOURNAL OF HEPATOLOGY, 2021, 75 : S249 - S249
  • [23] Pemazyre® (Pemigatinib) is available in Germany for the Treatment of Adults with locally advanced or metastatic Cholangiocarcinoma with Fusion or Rearrangement of the Fibroblast Growth Factor Receptor 2 (FGFR2)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 367 - 367
  • [24] Detection of Known and Novel FGFR2 Geneomic Alterations in Intrahepatic Cholangiocarcinoma
    Pu, Xiaohong
    Fu, Yao
    Fan, Xiangshan
    Chen, Jun
    Sun, Beicheng
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1405 - S1407
  • [25] FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma
    Cao, Zi
    Yang, Yichen
    Liu, Shasha
    Sun, Lin
    Liu, Yanxue
    Luo, Ye
    Wang, Jian
    Sun, Yan
    JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 235 - 246
  • [26] Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
    Lidsky, Michael E.
    Wang, Zechen
    Lu, Min
    Liu, Annie
    Hsu, S. David
    McCall, Shannon J.
    Sheng, Zhecheng
    Granek, Joshua A.
    Owzar, Kouros
    Anderson, Karen S.
    Wood, Kris C.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [27] Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
    Michael E. Lidsky
    Zechen Wang
    Min Lu
    Annie Liu
    S. David Hsu
    Shannon J. McCall
    Zhecheng Sheng
    Joshua A. Granek
    Kouros Owzar
    Karen S. Anderson
    Kris C. Wood
    npj Precision Oncology, 6
  • [28] FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
    Patel, Timil H.
    Marcus, Leigh
    Horiba, M. Naomi
    Donoghue, Martha
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Schuck, Robert N.
    Li, Yangbing
    Zhang, Xinyuan
    Zirkelbach, Jeanne Fourie
    Charlab, Rosane
    Liu, Jiang
    Yang, Yuching
    Lemery, Steven J.
    Pazdur, Richard
    Theoret, Marc R.
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 838 - 842
  • [29] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
    Vincenzo Mazzaferro
    Bassel F. El-Rayes
    Michele Droz dit Busset
    Christian Cotsoglou
    William P. Harris
    Nevena Damjanov
    Gianluca Masi
    Lorenza Rimassa
    Nicola Personeni
    Fadi Braiteh
    Vittorina Zagonel
    Kyriakos P. Papadopoulos
    Terence Hall
    Yunxia Wang
    Brian Schwartz
    Julia Kazakin
    Sherrie Bhoori
    Filippo de Braud
    Walid L. Shaib
    British Journal of Cancer, 2019, 120 : 165 - 171
  • [30] Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma
    Cleary, James M.
    Raghavan, Srivatsan
    Li, Yvonne Y.
    Spurr, Liam
    Wu, Qibiao
    Shi, Lei
    Brais, Lauren K.
    Odhiambo, Zunelly
    Goyal, Lipika
    Patel, Anuj K.
    Shinagare, Atul B.
    Clancy, Thomas E.
    Shapiro, Geoffrey
    Cerami, Ethan
    Sellers, William R.
    Hahn, William C.
    Cherniack, Andrew D.
    Bardeesy, Nabeel
    Meyerson, Matthew
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345